Europe Women’s Health Diagnostics Market, by Application (Breast Cancer Testing, Cervical Cancer Testing, Pregnancy and Fertility Testing, Ovarian Cancer Testing, Infectious Disease Testing, Ultrasound Tests, Sexually Transmitted Disease Testing, and Others), Tests (Biopsies, Other Breast Cancer Tests, Pregnancy and Fertility Testing, Lab-based Testing, Pregnancy Testing and Ovulation Prediction Kits, Fertility Monitors, Prenatal Genetic Screening and Carrier Testing, CF Testing, Down’s Syndrome and Edwards’ Syndrome Testing, TORCH Testing, Other Prenatal Genetic Disease Tests, Infectious Disease Testing, MRSA Testing, UTI Testing, Hepatitis Testing), and by End-User (Diagnostic and Imaging Centers, Hospitals and Clinics, and Home Care) – Industry Trends and Forecast to 2029
Market Analysis and Size
According to the World Health Organization, over 470 million women live in the European Region, accounting for just over half of the total population. Understanding the demographic and epidemiological changes occurring in this diverse Region, like as ageing and migration, requires an understanding of women's health. Furthermore, the GDP of the European Union region was around USD 18.8 trillion in 2018, according to the World Bank, and health spending is the second largest item of general government spending after social security spending. Total health spending by the federal government was 9.6 percent of GDP. This will increase healthcare infrastructure and the number of clinical laboratories and diagnostic facilities in Europe, boosting the market for women's health diagnostics in the coming year.
Data Bridge Market Research analyses that the women’s health diagnostics market which was USD 26.48 billion in 2021, would rocket up to USD 41.88 billion by 2029, and is expected to undergo a CAGR of 5.9% during the forecast period 2022-2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Women's health refers to the diagnosis and treatment of illnesses and diseases that may affect a woman's physical and mental well-being. Women's health includes birth control, sexually transmitted infections (STIs), gynaecology disorders, breast cancer, ovarian cancer, other female cancers, menopause, hormone therapy, osteoporosis, pregnancy and childbirth, sexual health, women and heart disease, and benign conditions affecting the function of the female reproductive organs.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Application (Breast Cancer Testing, Cervical Cancer Testing, Pregnancy and Fertility Testing, Ovarian Cancer Testing, Infectious Disease Testing, Ultrasound Tests, Sexually Transmitted Disease Testing, and Others), and by End-User (Diagnostic and Imaging Centers, Hospitals and Clinics, and Home Care)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Siemens (Germany), Hologic, Inc. (MA), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Abbott (U.S.), BD (NJ), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), NeuroLogica Corp.(U.S.A), Shimadzu Medical (India) pvt. Ltd. (Japan), GENERAL ELECTRIC (U.S.), Quest Diagnostics Incorporated (U.S.), Sysmex India Pvt. Ltd. (Japan), Hitachi, Ltd. (Japan), Canon Inc. (Japan), FUJIFILM Holdings Corporation (U.K)
|
|
Market Opportunities
|
|
Women’s Health Diagnostics Market Dynamics
Drivers
- Increasing incidence of chronic and lifestyle-related disorders
The expanding number of imaging and diagnostic centres, as well as the expanded usage of point-of-care and fast diagnostic tests. As the prevalence of osteoarthritis, ovarian cancer, breast cancer, and cervical cancer rises, the market for women's health diagnostics is growing. Breast cancer is the most frequent cancer in women and the second-most-common cancer in the globe. In 2018, nearly 2 million new cases were reported.
- Increase in the rate of approval of point-of-care diagnostic testing
The market is expected to grow as the number of diagnostic and imaging machines sold around the world rises. However, a surge in demand for the development of miniature diagnostic devices, as well as an increase in healthcare infrastructure and new marketing initiatives by key vendors in emerging countries, are expected to provide market expansion during the forecast period of 2022-2029.
- Increasing prevalence of osteoarthritis, ovarian cancer, breast cancer, and cervical cancer
Breast cancer is the most frequent cancer in women and the second-most-common cancer in the globe. According to Globocan 2020, 2,261,419 new cases of breast cancer will be diagnosed in 2020. The rising number of cases has resulted in increased sales of test kits for home use, which is expected to fuel the market's revenue growth throughout the forecast period. Increased acceptance of point-of-care diagnostic testing and an increase in the number of diagnostic and imaging equipment available globally are expected to drive the market forward.
Opportunities
Breast cancer's rising prevalence, greater research and development spending, and improvements in cancer diagnostics are all expected to accelerate segmental expansion. According to Globocan, roughly 2.26 million new instances of breast cancer were diagnosed in females worldwide in 2020, accounting for around 11.7 percent of all cancer cases. As the patient pool for breast cancer develops, demand for diagnostics is projected to climb even quicker. Product launches are another major factor in the market's expansion.
Restraints/Challenges
Patients' resistance to early screening, which needs considerable expenditures for detection, the possibility of over-diagnosis and overtreatment, and the fact that MRI scans are accurate yet time consuming and costly for patients are all problems that the women's health diagnostic market faces.
Diagnostic tests for women's health are costly, which is a significant barrier to market entry. The women's health diagnostic sector has considerable challenges due to a lack of information about various illnesses and diagnostic methodologies. Low-income companies and emerging economies are addressing market constraints in women's health diagnostics.
This women’s health diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the women’s health diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Women’s Health Diagnostics Market
Due to capital market and global economy uncertainty, limited transit options and travel restrictions created impediments to international trade and transportation during the COVID-19 pandemic, affecting the supply chain for women's health diagnostics and temporarily lowering demand. The advancement of this industry is impeded by unfavourable changes in rules and laws. According to major regulatory organisations, COVID-19 infection is more common in breast cancer patients than in healthy people. Screening, surgical operations, and diagnostic screenings at hospitals and breast cancer clinics have all been postponed or severely curtailed as a result.
Recent Development
- Roche announced in May 2019 that the VENTANA HER2 Dual ISH DNA Probe Cocktail assay for detecting the HER2 biomarker in gastric and breast cancer would be available. This would contribute to the company's product line being expanded.
Europe Women’s Health Diagnostics Market Scope
The women’s health diagnostics market is segmented on the basis of test, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
- Osteoporosis Testing
- Bone Densitometry
- In Vitro Blood Tests
- OVC Testing
- OVC Tumor Marker Tests
- OVC Diagnostic Imaging Tests
- Other OVC Tests
- Cervical Cancer Testing
- Pap Smears
- HPV Testing
- Breast Cancer Testing
- Mammography
Tests
- Biopsies
- Other Breast Cancer Tests
- Pregnancy and Fertility Testing
- Lab-based Testing
- Pregnancy Testing and Ovulation Prediction Kits
- Fertility Monitors
- Prenatal Genetic Screening and Carrier Testing
- CF Testing
- Down’s Syndrome and Edwards’ Syndrome Testing
- TORCH Testing
- Other Prenatal Genetic Disease Tests
- Infectious Disease Testing
- MRSA Testing
- UTI Testing
- Hepatitis Testing
- Tuberculosis Testing
- Other Infectious Disease Tests
- STD Testing
- CT/NG Testing
- HIV Testing
- Other STD Tests
- Ultrasound Tests
- Breast Imaging
- OB/GYN Imaging
End-User
- Hospitals and Clinics
- Diagnostic and Imaging Centers
- Home Care Settings
Women’s Health Diagnostics Market Regional Analysis/Insights
The women’s health diagnostics market is analysed and market size insights and trends are provided by country, test, application and end user as referenced above.
The countries covered in the women’s health diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The high prevalence of cancer among women, the rising incidence of lifestyle-related disorders, the high adoption of technologically advanced products, product launches, and government initiatives, the women's health diagnostic market in North America and Europe is expected to grow steadily.
By increasing campaigns on women's health issues and disease awareness, the Asia-Pacific region has improved its healthcare situation and has emerged as a growing participant in the women's health diagnostic market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The women’s health diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for women’s health diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the women’s health diagnostics market. The data is available for historic period 2010-2020.
Competitive Landscape and Women’s Health Diagnostics Market Share Analysis
The women’s health diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to women’s health diagnostics market.
Some of the major players operating in the women’s health diagnostics market are:
- Siemens (Germany)
- Hologic, Inc. (MA)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
- Abbott (U.S.)
- BD (NJ)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- NeuroLogica Corp.(U.S.A)
- Shimadzu Medical (India) pvt. Ltd. (Japan)
- GENERAL ELECTRIC (U.S.)
- Quest Diagnostics Incorporated (U.S.)
- Sysmex India Pvt. Ltd. (Japan)
- Hitachi, Ltd. (Japan)
- Canon Inc. (Japan)
- FUJIFILM Holdings Corporation (U.K)
SKU-